Artimplant strenghtens its market position

Artimplant has entered into an agreement with its licensee, Biomet Sports Medicine, Inc., to assume total responsibility for sales of ATR products.

Biomet has held the license rights for our Artelon® Tissue Reinforcement (ATR) products since 2005. During 2007, the agreement was renegotiated from exclusive to non-exclusive for the US market. In conjunction with this, Artimplant began prospecting the market independently with the aim of increasing sales of ATR products more quickly.

The decision by Artimplant to terminate the license agreement with Biomet is part of the new strategy of focusing exclusively on its own organization and own sales. The other license agreement, governing Artimplant's Spacer-products, was terminated at the year-end, and consequently we now have full responsibility for the sale of all products on all markets.

Through our new, reinforced organization in the USA, which has been in place since the end of last year, we have taken a major step forward in our development. Sales at the end of last year and the beginning of this year have been very positive compared to previous years. We feel very optimistic about the future and the target of achieving a positive cash flow on a monthly basis during the fourth quarter of this year remains firm.

Västra Frölunda, March 20, 2012
Kjell Thörnbring

For further information, please contact:

Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone:  +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on March 20, 2012 at 8:45 AM (Swedish time).

Tags: